Literature DB >> 14722298

Enterovirus capsid interactions with decay-accelerating factor mediate lytic cell infection.

Nicole G Newcombe1, E Susanne Johansson, Gough Au, A Michael Lindberg, Richard D Barry, Darren R Shafren.   

Abstract

The cellular receptor usage of numerous human enteroviruses can differ significantly between low-cell-culture-passaged clinical isolates and highly laboratory-passaged prototype strains. The prototype strain of coxsackievirus A21 (CVA21) displays a dual-receptor specificity as determined with a receptor complex consisting of decay-accelerating factor (DAF) and intercellular adhesion molecule 1 (ICAM-1). In this study, the cellular receptor interactions of low-cell-passage CVA21 clinical isolates with respect to their interactions with cell surface-expressed DAF and ICAM-1 were compared to those of the CVA21 prototype (Kuykendall) strain. Dual-receptor usage of DAF and ICAM-1 by CVA21 clinical isolates was confirmed by cell transfection and radiolabeled binding assays. The cellular attachment of clinical and prototype CVA21 strains to cells that coexpressed DAF and ICAM-1 was not additive compared to the viral binding to cells expressing one or other receptor. In fact, the binding data suggest there is an inhibition of CVA21 cellular attachment in environments where high-level coexpression of both DAF and ICAM-1 occurs. Antibody cross-linking of DAF rendered cells susceptible to lytic infection by the CVA21 clinical isolates. In a novel finding, three clinical isolates could, to various degrees, infect and lyse DAF-expressing cells in the absence of DAF-antibody cross-linking and ICAM-1 expression. Sequence analysis of the P1 region of clinical and prototype virus genomes identified a number of coding changes that may contribute to the observed enhanced DAF usage phenotype of the clinical CVA21 isolates. None of the amino acid changes was located in the previously postulated ICAM-1 footprint, a receptor-binding environment that was conserved on the capsid surface of all CVA21 clinical isolates. Taken together, the data suggest that community-circulating strains of CVA21 can infect target cells expressing either ICAM-1 or DAF alone and that such interactions extend tissue tropism and impact directly on viral pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14722298      PMCID: PMC321397          DOI: 10.1128/jvi.78.3.1431-1439.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  43 in total

1.  Characterization of the echovirus 7 receptor: domains of CD55 critical for virus binding.

Authors:  N A Clarkson; R Kaufman; D M Lublin; T Ward; P A Pipkin; P D Minor; D J Evans; J W Almond
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

2.  Interaction between echovirus 7 and its receptor, decay-accelerating factor (CD55): evidence for a secondary cellular factor in A-particle formation.

Authors:  R M Powell; T Ward; D J Evans; J W Almond
Journal:  J Virol       Date:  1997-12       Impact factor: 5.103

3.  Amplification and cloning of complete enterovirus genomes by long distance PCR.

Authors:  A M Lindberg; C Polacek; S Johansson
Journal:  J Virol Methods       Date:  1997-05       Impact factor: 2.014

4.  Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5.

Authors:  J M Bergelson; J A Cunningham; G Droguett; E A Kurt-Jones; A Krithivas; J S Hong; M S Horwitz; R L Crowell; R W Finberg
Journal:  Science       Date:  1997-02-28       Impact factor: 47.728

5.  Clinical coxsackievirus B isolates differ from laboratory strains in their interaction with two cell surface receptors.

Authors:  J M Bergelson; J F Modlin; W Wieland-Alter; J A Cunningham; R L Crowell; R W Finberg
Journal:  J Infect Dis       Date:  1997-03       Impact factor: 5.226

6.  Cardiovirulent coxsackieviruses and the decay-accelerating factor (CD55) receptor.

Authors:  T A Martino; M Petric; M Brown; K Aitken; C J Gauntt; C D Richardson; L H Chow; P P Liu
Journal:  Virology       Date:  1998-05-10       Impact factor: 3.616

7.  Coxsackievirus A21 binds to decay-accelerating factor but requires intercellular adhesion molecule 1 for cell entry.

Authors:  D R Shafren; D J Dorahy; R A Ingham; G F Burns; R D Barry
Journal:  J Virol       Date:  1997-06       Impact factor: 5.103

8.  Antibody binding to individual short consensus repeats of decay-accelerating factor enhances enterovirus cell attachment and infectivity.

Authors:  D R Shafren; D J Dorahy; R F Thorne; T Kinoshita; R D Barry; G F Burns
Journal:  J Immunol       Date:  1998-03-01       Impact factor: 5.422

9.  Mouse cells expressing human intercellular adhesion molecule-1 are susceptible to infection by coxsackievirus A21.

Authors:  D R Shafren; D J Dorahy; S J Greive; G F Burns; R D Barry
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

10.  Attachment of coxsackievirus B3 variants to various cell lines: mapping of phenotypic differences to capsid protein VP1.

Authors:  M Schmidtke; H C Selinka; A Heim; B Jahn; M Tonew; R Kandolf; A Stelzner; R Zell
Journal:  Virology       Date:  2000-09-15       Impact factor: 3.616

View more
  7 in total

1.  Interaction with coxsackievirus and adenovirus receptor, but not with decay-accelerating factor (DAF), induces A-particle formation in a DAF-binding coxsackievirus B3 isolate.

Authors:  Aaron M Milstone; JenniElizabeth Petrella; Melissa D Sanchez; Mariam Mahmud; J Charles Whitbeck; Jeffrey M Bergelson
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

2.  Enhanced cellular receptor usage by a bioselected variant of coxsackievirus a21.

Authors:  E Susanne Johansson; Li Xing; R Holland Cheng; Darren R Shafren
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

3.  Novel role for decay-accelerating factor in coxsackievirus A21-mediated cell infectivity.

Authors:  Nicole G Newcombe; Leone G Beagley; Dale Christiansen; Bruce E Loveland; E Susanne Johansson; Ken W Beagley; Richard D Barry; Darren R Shafren
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

Review 4.  Respiratory protease/antiprotease balance determines susceptibility to viral infection and can be modified by nutritional antioxidants.

Authors:  Megan Meyer; Ilona Jaspers
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-04-17       Impact factor: 5.464

5.  Complexity and ultrastructure of infectious extracellular vesicles from cells infected by non-enveloped virus.

Authors:  Jie E Yang; Evan D Rossignol; Deborah Chang; Joseph Zaia; Isaac Forrester; Kiran Raja; Holly Winbigler; Daniela Nicastro; William T Jackson; Esther Bullitt
Journal:  Sci Rep       Date:  2020-05-14       Impact factor: 4.379

6.  Structure of Human Enterovirus 70 and Its Inhibition by Capsid-Binding Compounds.

Authors:  Tibor Füzik; Jana Moravcová; Sergei Kalynych; Pavel Plevka
Journal:  J Virol       Date:  2022-08-08       Impact factor: 6.549

7.  Development of intravenously administered synthetic RNA virus immunotherapy for the treatment of cancer.

Authors:  Edward M Kennedy; Agnieszka Denslow; Jacqueline Hewett; Lingxin Kong; Ana De Almeida; Jeffrey D Bryant; Jennifer S Lee; Judy Jacques; Sonia Feau; Melissa Hayes; Elizabeth L McMichael; Daniel Wambua; Terry Farkaly; Amal A Rahmeh; Lauren Herschelman; Danielle Douglas; Jacob Spinale; Sanmit Adhikari; Jessica Deterling; Matt Scott; Brian B Haines; Mitchell H Finer; Ted T Ashburn; Christophe Quéva; Lorena Lerner
Journal:  Nat Commun       Date:  2022-10-07       Impact factor: 17.694

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.